Details of the Drug Combinations

General Information of This Drug (ID: DM0LPI9)

Drug Name

Netarsudil DM0LPI9

Synonyms

UNII-W6I5QDT7QI; W6I5QDT7QI; Netarsudil mesylate; Netarsudil [USAN]; AR-11324 free base; Netarsudil [USAN:INN]; Netarsudil (USAN/INN); GTPL9322; SCHEMBL16036278; ZINC113149554; AR11324; AR-11324; ester 60; 1628418-15-4

Indication

Disease Entry	ICD 11	Status	REF
Open-angle glaucoma	9C61	Approved	[1]
Glaucoma/ocular hypertension	9C61	Phase 2	[2]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Netarsudil + Marizomib	DCCR6B2	Marizomib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
------------------------------------------------------------------------------------

References

1	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
2	Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015 Jan;24(1):51-4.
3	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.